SavedAdd your journal

Journals / Mikrobiyoloji Bülteni / 2013 / Cilt: 47 - Sayı: 3

APOBEC3 hypermutations in HIV-1 infected cases in Turkey

Türkiye’de HIV-1 ile enfekte olgularda APOBEC3 hipermutasyonları

MURAT SAYAN
FUNDA ŞİMŞEK
Nurgül CERAN
Başak DOKUZOĞUZ
Haluk ERAKSOY
Pages
482–492
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The prevalence of overall APOBEC 3G/F hypermutations was 2.5% (13/515) in HIV-1 pol gene sequences in study group, and the rates were 2% (8/394) and 4.1% (5/121) in antiretroviral naive and treatment groups, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Host genetic factors may play an effective role on the human immunodeficiency virus (HIV) pathogenesis.
📊
Key Findings & Data:APOBEC3 (apolipoprotein B mRNA editing enzyme catalytic polypeptide like-3) proteins are cellular antiviral proteins which inhibits HIV replication in the absence of vif (virion infectivity factor).
💡
Conclusion & Impact:The prevalence of overall APOBEC 3G/F hypermutations was 2.5% (13/515) in HIV-1 pol gene sequences in study group, and the rates were 2% (8/394) and 4.1% (5/121) in antiretroviral naive and treatment groups, respectively.
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Host genetic factors may play an effective role on the human immunodeficiency virus (HIV) pathogenesis. APOBEC3 (apolipoprotein B mRNA editing enzyme catalytic polypeptide like-3) proteins are cellular antiviral proteins which inhibits HIV replication in the absence of vif (virion infectivity factor). In this study, we aimed to determine the APOBEC 3G/F hypermutations in HIV-1 strains isolated in Turkey. A total of 515 HIV-1 infected patients between June 2009 - February 2012 were included in the study. Three hundred ninety four cases were newly diagnosed antiretroviral-naive patients [349 male, 45 female; me- dain age (range): 37.1 (2-69) years; median CD4+ T-cell count (range): 340 (1-1660) mm3; median HIV- RNA load (range): 5.76 + E5 (8.7 + E2-9.4 + E6) IU/ml] and 121 were under HAART therapy [99 male, 22 female; median age (range): 40.7 (20-70) years; median CD4+ T-cell count (range): 195 (6-720) mm3; median HIV-RNA load (range): 5.4 + E5 (1.37 + E3-1.07 + E7) IU/ml]. APOBEC 3G/F hypermutations in HIV-1 pol sequences (reverse transcriptase; codons 41-238 and protease; codons 1-99) analysed by nested RT-PCR and direct sequencing techniques. APOBEC 3G/F hypermutations have been determi- ned by using of HIVdb-Stanford algorithm. The prevalence of overall APOBEC 3G/F hypermutations was 2.5% (13/515) in HIV-1 pol gene sequences in study group, and the rates were 2% (8/394) and 4.1% (5/121) in antiretroviral naive and treatment groups, respectively. However, the location and marker hypermutations of determined APOBEC in the HIV-1 pol gene sequences were RT and 3G in the Turkish patients. The hypermutated HIV-1 strains identified in HIV-1 infected patients may facilitate our understanding the nature and the consequences of HIV-1 infections. Moreover, investigations of the motif and frequency of APOBEC 3G/F hypermutations in HIV-1 proviral DNA samples and understanding their relationships with HIV-1 subtypes in Turkish patients would be beneficial.

Özet

Konak genetik faktörleri insan immün yetmezlik virusu (HIV)’nun patogenezi üzerinde etkili olabilmektedir. Bunlardan biri olan APOBEC3 (apolipoprotein B mRNA editing enzyme catalytic polypeptidelike 3) proteinleri, HIV vif (virion infektivite faktörü) aksesuvar proteini ile sürekli bir etkileşim içinde olup, HIV ters transkripsiyonunda oluşturduğu hasar ile antiretroviral aktivite göstermektedir. Bu çalışmada, ülkemizde elde edilen HIV-1 izolatlarında APOBEC 3G/F hipermutasyonlarının tanımlanması amaçlanmıştır. Çalışma grubu, Haziran 2009-Şubat 2012 tarihleri arasında, yeni tanı almış 394 hasta [349 erkek, 45 kadın; ortanca yaş (aralık): 37.1 (2-69) yıl; ortanca CD4+ T-hücre sayısı (aralık): 340 (1-1660) mm3; ortanca HIV-RNA yükü (aralık): 5.76 + E5 (8.7 + E2-9.4 + E6) IU/ml] ile HAART tedavisi altında 121 hasta [99 erkek, 22 kadın; ortanca yaş (aralık): 40.7 (20-70) yıl; ortanca CD4+ T-hücre sayısı (aralık): 195 (6- 720) mm3; ortanca HIV-RNA yükü (aralık): 5.4 + E5 (1.37 + E3-1.07 + E7) IU/ml] olmak üzere toplam 515 HIV-1 pozitif hastadan oluşturulmuştur. HIV-1 pol geninin ters transkriptaz (kodon 41-238) ve proteaz kangalları (kodon 1-99) nested RT-PCR ile çoğaltılmış ve dizilenmiştir. APOBEC 3G/F hipermutasyonları HIVdb-Stanford algoritması kullanılarak tanımlanmıştır. Çalışma grubunda yer alan hastaların %2.5 (13/515)’inde HIV-1 pol geni dizilerinde APOBEC 3G/F hipermutasyonları saptanmıştır. Hastalarımızda sıklıkla HIV-1 pol geninin RT kangalında ve 3G motifi olarak belirlenen hipermutasyonlar, tedavi-naif hastalarda %2 (8/394), HAART tedavisi altındaki hastalarda ise %4.1 (5/121) oranında tespit edilmiştir. HIV- 1 enfeksiyonlarında APOBEC 3G/F hipermutasyonlarının ortaya çıkarılması, HIV-1 enfeksiyonlarının doğasını ve sonuçlarını kavramamıza yardımcı olabilir. Öte yandan APOBEC 3G/F hipermutasyon motif ve sıklığının CD4+ T lenfositlerden elde edilecek HIV-1 proviral DNA örneklerinde araştırılması ve ülkemizde dolaşımda bulunan HIV-1 alttipleri ile ilgisinin ortaya çıkarılması yararlı olabilir.

🔖

Cite This Article

SAYAN, M., ŞİMŞEK, F., CERAN, N., DOKUZOĞUZ, B., ERAKSOY, H. (2013). APOBEC3 hypermutations in HIV-1 infected cases in Turkey. Mikrobiyoloji Bülteni, Cilt: 47 - Sayı: 3, 482–492. https://ajindex.com/articles/298646

References (14)

  1. Turner BG, Summers MF. Structural biology of HIV. J Mol Biol 1999; 285(1): 1-32
  2. Albin JS, Harris RS. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med 2010; 12: e4
  3. Wissing S, Galloway NL, Greene WC. HIV-1 vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med 2010; 31(5): 383-97
  4. Wood N, Bhattacharya T, Keele BF, et al. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 2009; 5(5): e1000414
  5. Armitage AE, Deforche K, Chang C, et al. APOBEC3G - induced hypermutation of human immunodeficiency virus type - 1 is typically a discrete ‘’all or nothing’’ phenomenon. PLoS Genet 2012; 8(3): e1002550
  6. Vartanian JP, Meyerhans A, Asjo B, Wain-Hobson S. Selection, recombination, and G→A hypermutation of human immunodeficiency virus type 1 genomes. J Virol 1991; 65(4): 1779-88
  7. Kieffer TL, Kwon P, Nettles RE, et al. G3A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+T cells in vivo. J Virol 2005; 79(3): 1975-80
  8. Rose PP, Korber BT. Detecting hypermutations in viral sequences with an emphasis on G→A hypermutation. Bioinformatics 2000; 16(4): 400-1
  9. Günther S, Sommer G, Plikat U, et al. Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G→A hypermutation. Virology 1997; 235(1): 104-8
  10. European AIDS Clinical Society (EACS) Guidelines. Version 6, October 2011. www.europeanaidsclinicalso-ciety.org
  11. Centers for Disease Control and Prevention. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunode- ficiency syndrome. MMWR Recomm Rep 1999; 48(RR-13): 1-27, 29-31
  12. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4(3): e4724
  13. Gifford RJ, Rhee SY, Eriksson N, et al. Sequence editing by apolipoprotein B RNA-editing catalytic component-B and epidemiological surveillance of transmitted HIV-1 drug resistance. AIDS 2008; 22(6): 717-25
  14. Sayan M, Kumbasar Karaosmanoğlu H, Mete B, et al. Molecular epidemiological analysis of HIV-1 pol gene sequences isolated in Istanbul, Turkey. Mikrobiyol Bul 2013; 47(1): 87-97